DNM1L

Across TCGA pan-cancer cohorts, DNM1L RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated DNM1L data layer compared with 3 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher DNM1L RNA is associated with worse overall survival. In most high-consensus cancer types, elevated DNM1L expression acts as an unfavorable survival marker, although some lineages such as READ and THCA show a favorable association.

LIHC, MESO, and CESC are the cancer types where DNM1L RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.711	0.837	<.001	82	view →
MESO	OS	Quartile	All	0.412	0.752	.001	67	view →
CESC	DFS	Tertile	III,IV	0.460	0.899	.002	36	view →
UVM	DFS	Quartile	III,IV	0.095	1.000	.006	33	view →
HNSC	OS	Median	All	0.628	0.786	.003	32	view →
LUAD	DFS	Median	IV	0.311	0.691	.001	21	view →
SARC	OS	Median	All	0.439	0.753	<.001	18	view →
DLBC	DFS	Median	All	0.629	1.000	.017	15	view →
READ	OS	Tertile	II,III,IV	0.907	0.333	.018	15	view →
KIRC	DFS	Median	IV	0.228	0.477	.008	10	view →
ESCA	DFS	Quartile	All	0.384	0.641	.012	9	view →
PAAD	OS	Median	III,IV	0.629	1.000	.022	7	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

DNM1L–LIHC (OS)

Open the LIHC breakdown →